Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | Rspo2 |
| Gene Name: | RSPO2 |
| Protein Full Name: | R-spondin-2 |
| Alias: | Cristin2; Mgc35555; Mgc43342; R-spondin 2 homologue (xenopus laevis); R-spondin family, member 2 |
| Mass (Da): | 28315 |
| Number AA: | 243 |
| UniProt ID: | Q6UXX9 |
| Locus ID: | 340419 |
| COSMIC ID: | RSPO2 |
| Gene location on chromosome: | 8q23.1 |
| Cancer protein type: | UNCLEAR |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | UNCLEAR |
| Number of cancer specimens: | 19717 |
| Percent of cancer specimens with mutations: | 0.49 |
| Normal role description: | RSPO2 is a secreted protein which activates Wnt signalling through activation of beta-catenin. RSPO2 may signal through the frizzled/LRP receptor but may also have its own distinct receptor. RSPO2 was found to promote gastrointestinal epithelial cell proliferation in a beta-catenin dependent mechanism. Artificial overexpression of RSPO2 inhibited TGF-beta apoptosis and promoted myogenesis in a xenopus oocyte system. Mis-sense and silent mutations of RSPO2 have ben detected in lung, ovarian, pancreatic and skin cancer however their functional effects are not well characterized. Due to RSPO2's role in activating Wnt signalling it may function as an oncogene to cause cell proliferation and growth in cancer development. |